Jeffrey Bennett
Concepts (552)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuromyelitis Optica | 87 | 2026 | 139 | 19.030 |
Why?
| | Aquaporin 4 | 59 | 2026 | 100 | 8.910 |
Why?
| | Multiple Sclerosis | 35 | 2026 | 484 | 5.860 |
Why?
| | Autoantibodies | 51 | 2025 | 1492 | 5.010 |
Why?
| | Immunoglobulin G | 52 | 2024 | 898 | 4.320 |
Why?
| | Optic Neuritis | 15 | 2023 | 46 | 4.000 |
Why?
| | Antibodies, Monoclonal, Humanized | 24 | 2026 | 929 | 2.860 |
Why?
| | B-Lymphocytes | 16 | 2024 | 884 | 2.210 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 17 | 2024 | 55 | 1.690 |
Why?
| | Optic Nerve | 12 | 2023 | 67 | 1.590 |
Why?
| | Immunologic Factors | 6 | 2025 | 251 | 1.500 |
Why?
| | Optic Nerve Diseases | 5 | 2022 | 50 | 1.480 |
Why?
| | Remyelination | 2 | 2025 | 15 | 1.470 |
Why?
| | Astrocytes | 15 | 2025 | 219 | 1.440 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 3 | 2023 | 28 | 1.340 |
Why?
| | Complement Inactivating Agents | 3 | 2026 | 67 | 1.120 |
Why?
| | Neuroglia | 5 | 2024 | 173 | 1.000 |
Why?
| | Demyelinating Diseases | 7 | 2020 | 83 | 0.990 |
Why?
| | Antibodies, Monoclonal | 16 | 2023 | 1477 | 0.960 |
Why?
| | Tomography, Optical Coherence | 7 | 2023 | 263 | 0.960 |
Why?
| | Complement C5 | 1 | 2025 | 34 | 0.910 |
Why?
| | Magnetic Resonance Imaging | 16 | 2026 | 3803 | 0.900 |
Why?
| | Humans | 150 | 2026 | 143806 | 0.900 |
Why?
| | Macaca mulatta | 8 | 2024 | 191 | 0.860 |
Why?
| | Epitopes | 8 | 2025 | 489 | 0.850 |
Why?
| | Cerebellum | 4 | 2025 | 222 | 0.840 |
Why?
| | Retinal Degeneration | 2 | 2023 | 40 | 0.830 |
Why?
| | Brain | 12 | 2024 | 2899 | 0.800 |
Why?
| | Natalizumab | 4 | 2020 | 40 | 0.800 |
Why?
| | Complement System Proteins | 7 | 2019 | 313 | 0.790 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 4 | 2023 | 68 | 0.790 |
Why?
| | Methylprednisolone | 1 | 2023 | 64 | 0.780 |
Why?
| | Animals | 65 | 2025 | 38065 | 0.760 |
Why?
| | Optic Neuropathy, Ischemic | 4 | 2015 | 31 | 0.750 |
Why?
| | Immunosuppressive Agents | 7 | 2022 | 859 | 0.730 |
Why?
| | Disease Models, Animal | 16 | 2025 | 4538 | 0.710 |
Why?
| | Immunoglobulin Heavy Chains | 4 | 2015 | 85 | 0.700 |
Why?
| | Blood-Brain Barrier | 5 | 2022 | 154 | 0.700 |
Why?
| | Autoimmunity | 4 | 2017 | 927 | 0.690 |
Why?
| | Myelin Sheath | 7 | 2025 | 166 | 0.680 |
Why?
| | Fingolimod Hydrochloride | 1 | 2020 | 43 | 0.650 |
Why?
| | Immunotherapy | 4 | 2020 | 659 | 0.630 |
Why?
| | Adult | 46 | 2026 | 40083 | 0.610 |
Why?
| | Complement C1q | 1 | 2019 | 33 | 0.600 |
Why?
| | Plasma Cells | 7 | 2017 | 74 | 0.590 |
Why?
| | Complement Activation | 4 | 2022 | 413 | 0.590 |
Why?
| | Oligodendrocyte Precursor Cells | 1 | 2019 | 23 | 0.580 |
Why?
| | Glial Fibrillary Acidic Protein | 5 | 2024 | 112 | 0.580 |
Why?
| | Pseudotumor Cerebri | 2 | 2016 | 31 | 0.580 |
Why?
| | Middle Aged | 43 | 2026 | 35398 | 0.570 |
Why?
| | Cell Membrane | 3 | 2017 | 709 | 0.570 |
Why?
| | Inflammation | 11 | 2023 | 2882 | 0.570 |
Why?
| | Papilledema | 4 | 2023 | 44 | 0.570 |
Why?
| | Aminopyridines | 1 | 2019 | 119 | 0.560 |
Why?
| | Central Nervous System | 5 | 2023 | 269 | 0.560 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 4 | 2021 | 80 | 0.550 |
Why?
| | Mice | 32 | 2025 | 18414 | 0.550 |
Why?
| | Pyrroles | 1 | 2019 | 211 | 0.550 |
Why?
| | Herpesvirus 3, Human | 7 | 2015 | 336 | 0.540 |
Why?
| | Organic Chemicals | 1 | 2019 | 129 | 0.540 |
Why?
| | Double-Blind Method | 10 | 2025 | 2021 | 0.540 |
Why?
| | Female | 66 | 2026 | 77403 | 0.540 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2017 | 50 | 0.530 |
Why?
| | Glucocorticoids | 2 | 2019 | 542 | 0.530 |
Why?
| | Microglia | 2 | 2019 | 262 | 0.520 |
Why?
| | CHO Cells | 8 | 2019 | 167 | 0.510 |
Why?
| | Transverse Sinuses | 1 | 2016 | 8 | 0.510 |
Why?
| | Registries | 1 | 2025 | 2245 | 0.510 |
Why?
| | Disease Management | 2 | 2018 | 649 | 0.510 |
Why?
| | Biomarkers | 13 | 2025 | 4242 | 0.500 |
Why?
| | Heat-Shock Proteins | 1 | 2017 | 140 | 0.500 |
Why?
| | Spinal Cord | 8 | 2023 | 379 | 0.500 |
Why?
| | Cricetulus | 7 | 2019 | 112 | 0.490 |
Why?
| | Antigens, CD19 | 5 | 2022 | 140 | 0.490 |
Why?
| | Recombinant Proteins | 8 | 2019 | 1372 | 0.490 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2016 | 53 | 0.490 |
Why?
| | Retina | 5 | 2023 | 324 | 0.480 |
Why?
| | Mutagenesis | 2 | 2019 | 184 | 0.460 |
Why?
| | Stents | 2 | 2016 | 543 | 0.440 |
Why?
| | Male | 51 | 2026 | 71658 | 0.440 |
Why?
| | Giant Cell Arteritis | 5 | 2020 | 49 | 0.420 |
Why?
| | Herpesvirus 4, Human | 2 | 2012 | 177 | 0.420 |
Why?
| | Oligodendroglia | 4 | 2025 | 181 | 0.420 |
Why?
| | Optic Atrophy | 2 | 2011 | 8 | 0.410 |
Why?
| | Temporal Arteries | 4 | 2015 | 44 | 0.410 |
Why?
| | Diffusion Magnetic Resonance Imaging | 2 | 2006 | 156 | 0.410 |
Why?
| | Mice, Inbred C57BL | 12 | 2025 | 6055 | 0.400 |
Why?
| | Intracranial Hypotension | 2 | 2025 | 61 | 0.400 |
Why?
| | Recurrence | 8 | 2026 | 1122 | 0.390 |
Why?
| | Peptide Fragments | 4 | 2023 | 702 | 0.380 |
Why?
| | Antigens, Viral | 3 | 2015 | 179 | 0.380 |
Why?
| | Flow Cytometry | 9 | 2023 | 1192 | 0.370 |
Why?
| | Axons | 2 | 2022 | 199 | 0.370 |
Why?
| | Myelin Basic Protein | 6 | 2018 | 44 | 0.360 |
Why?
| | Wolfram Syndrome | 1 | 2011 | 4 | 0.360 |
Why?
| | Retinal Ganglion Cells | 3 | 2016 | 120 | 0.360 |
Why?
| | Autoantigens | 5 | 2025 | 427 | 0.360 |
Why?
| | Visual Acuity | 6 | 2021 | 479 | 0.360 |
Why?
| | Aged | 24 | 2026 | 25356 | 0.350 |
Why?
| | Hemodynamics | 1 | 2016 | 1117 | 0.350 |
Why?
| | Central Nervous System Infections | 1 | 2011 | 35 | 0.350 |
Why?
| | Cricetinae | 6 | 2019 | 301 | 0.340 |
Why?
| | Gene Targeting | 1 | 2011 | 82 | 0.340 |
Why?
| | Organ Culture Techniques | 5 | 2018 | 157 | 0.340 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2012 | 100 | 0.330 |
Why?
| | Nerve Degeneration | 1 | 2010 | 49 | 0.330 |
Why?
| | Stilbenes | 1 | 2010 | 37 | 0.330 |
Why?
| | Prospective Studies | 11 | 2025 | 7915 | 0.330 |
Why?
| | Nerve Regeneration | 1 | 2010 | 58 | 0.330 |
Why?
| | Eye Diseases | 2 | 2020 | 98 | 0.330 |
Why?
| | Young Adult | 17 | 2025 | 13992 | 0.320 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 2 | 2010 | 38 | 0.320 |
Why?
| | Nerve Tissue Proteins | 3 | 2014 | 607 | 0.320 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 4 | 2019 | 23 | 0.310 |
Why?
| | Immune System Phenomena | 1 | 2009 | 3 | 0.300 |
Why?
| | Meningioma | 2 | 2023 | 89 | 0.300 |
Why?
| | Virus Diseases | 1 | 2011 | 218 | 0.300 |
Why?
| | Rats | 12 | 2021 | 5610 | 0.300 |
Why?
| | Cell Survival | 2 | 2019 | 1136 | 0.290 |
Why?
| | Adolescent | 18 | 2024 | 22520 | 0.290 |
Why?
| | Amino Acid Sequence | 7 | 2015 | 2167 | 0.290 |
Why?
| | Nervous System Diseases | 2 | 2020 | 280 | 0.290 |
Why?
| | Rats, Inbred Lew | 7 | 2021 | 106 | 0.280 |
Why?
| | Immunoglobulins, Intravenous | 2 | 2022 | 130 | 0.280 |
Why?
| | Neurology | 2 | 2007 | 113 | 0.270 |
Why?
| | Protein Binding | 7 | 2025 | 2265 | 0.270 |
Why?
| | Ophthalmology | 2 | 2007 | 116 | 0.270 |
Why?
| | Cerebral Cortex | 3 | 2023 | 464 | 0.260 |
Why?
| | Antibodies | 3 | 2017 | 402 | 0.260 |
Why?
| | Peptide Library | 5 | 2025 | 95 | 0.260 |
Why?
| | Neurodegenerative Diseases | 1 | 2009 | 143 | 0.260 |
Why?
| | Oligoclonal Bands | 3 | 2011 | 25 | 0.250 |
Why?
| | Immunization, Passive | 3 | 2020 | 88 | 0.250 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2006 | 47 | 0.250 |
Why?
| | T-Lymphocytes | 3 | 2023 | 2036 | 0.250 |
Why?
| | Mutation | 6 | 2019 | 4059 | 0.250 |
Why?
| | Corpus Callosum | 1 | 2006 | 72 | 0.250 |
Why?
| | Antibody Formation | 1 | 2007 | 297 | 0.240 |
Why?
| | Transcriptome | 4 | 2020 | 1029 | 0.240 |
Why?
| | Gyrus Cinguli | 2 | 2024 | 93 | 0.240 |
Why?
| | Proteomics | 2 | 2012 | 1162 | 0.240 |
Why?
| | Herpes Zoster | 3 | 2015 | 320 | 0.240 |
Why?
| | Atrophy | 2 | 2023 | 198 | 0.230 |
Why?
| | B-Lymphocyte Subsets | 2 | 2024 | 79 | 0.230 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2025 | 57 | 0.220 |
Why?
| | Immunodominant Epitopes | 2 | 2017 | 27 | 0.220 |
Why?
| | Syndecan-1 | 4 | 2011 | 41 | 0.220 |
Why?
| | Myasthenia Gravis | 2 | 2022 | 23 | 0.220 |
Why?
| | Cell Adhesion Molecules | 1 | 2006 | 180 | 0.220 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2025 | 68 | 0.220 |
Why?
| | Retrospective Studies | 12 | 2026 | 16781 | 0.220 |
Why?
| | Lupus Vasculitis, Central Nervous System | 1 | 2024 | 11 | 0.220 |
Why?
| | Acute Disease | 3 | 2018 | 1015 | 0.210 |
Why?
| | Genetic Diseases, Inborn | 1 | 2004 | 46 | 0.210 |
Why?
| | Spastic Paraplegia, Hereditary | 1 | 2024 | 12 | 0.210 |
Why?
| | Cerebellar Ataxia | 1 | 2024 | 13 | 0.210 |
Why?
| | Neurofilament Proteins | 1 | 2024 | 63 | 0.210 |
Why?
| | Touch Perception | 1 | 2024 | 20 | 0.210 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2 | 2020 | 28 | 0.210 |
Why?
| | Consciousness | 1 | 2024 | 32 | 0.210 |
Why?
| | Nystagmus, Pathologic | 1 | 2024 | 20 | 0.210 |
Why?
| | Blindness, Cortical | 1 | 2003 | 6 | 0.210 |
Why?
| | Diagnosis, Differential | 6 | 2023 | 1505 | 0.210 |
Why?
| | Proteoglycans | 1 | 2004 | 109 | 0.210 |
Why?
| | Proteolipids | 1 | 2023 | 28 | 0.200 |
Why?
| | Risk Assessment | 4 | 2021 | 3582 | 0.200 |
Why?
| | Paraplegia | 1 | 2024 | 61 | 0.200 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2016 | 184 | 0.200 |
Why?
| | Epitope Mapping | 4 | 2017 | 61 | 0.200 |
Why?
| | Enzyme Inhibitors | 1 | 2007 | 840 | 0.200 |
Why?
| | White Matter | 1 | 2025 | 146 | 0.200 |
Why?
| | Seroconversion | 1 | 2023 | 50 | 0.190 |
Why?
| | Neuroprotection | 1 | 2023 | 45 | 0.190 |
Why?
| | Immune System | 1 | 2004 | 183 | 0.190 |
Why?
| | Lupus Erythematosus, Systemic | 2 | 2023 | 235 | 0.190 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2023 | 147 | 0.190 |
Why?
| | Cells, Cultured | 7 | 2016 | 4183 | 0.190 |
Why?
| | Incidence | 3 | 2025 | 2848 | 0.180 |
Why?
| | Disease Progression | 4 | 2026 | 2862 | 0.180 |
Why?
| | Molecular Sequence Data | 5 | 2011 | 2944 | 0.180 |
Why?
| | Vision Disorders | 2 | 2021 | 175 | 0.180 |
Why?
| | Zika Virus | 1 | 2023 | 132 | 0.180 |
Why?
| | Hippocampus | 2 | 2021 | 950 | 0.180 |
Why?
| | Mice, Transgenic | 5 | 2018 | 2194 | 0.180 |
Why?
| | Gene Expression Profiling | 3 | 2020 | 1794 | 0.180 |
Why?
| | Leukocytes, Mononuclear | 2 | 2023 | 589 | 0.180 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 498 | 0.180 |
Why?
| | Antibody Affinity | 2 | 2019 | 60 | 0.170 |
Why?
| | Patient Reported Outcome Measures | 1 | 2025 | 463 | 0.170 |
Why?
| | Protein Isoforms | 4 | 2017 | 404 | 0.170 |
Why?
| | Zika Virus Infection | 1 | 2023 | 169 | 0.170 |
Why?
| | Pre-Eclampsia | 1 | 2003 | 204 | 0.170 |
Why?
| | Autoimmune Diseases of the Nervous System | 1 | 2021 | 30 | 0.170 |
Why?
| | Internationality | 2 | 2019 | 158 | 0.170 |
Why?
| | Comorbidity | 2 | 2024 | 1681 | 0.170 |
Why?
| | Immunogenicity, Vaccine | 1 | 2020 | 35 | 0.170 |
Why?
| | Schizophrenia | 2 | 2022 | 442 | 0.170 |
Why?
| | Lymphocyte Activation | 2 | 2020 | 1143 | 0.160 |
Why?
| | Immunoglobulin Light Chains | 2 | 2015 | 51 | 0.160 |
Why?
| | Receptors, Interleukin-6 | 1 | 2020 | 46 | 0.160 |
Why?
| | Azathioprine | 1 | 2020 | 51 | 0.160 |
Why?
| | Animals, Newborn | 3 | 2018 | 882 | 0.160 |
Why?
| | Cell Proliferation | 3 | 2020 | 2542 | 0.160 |
Why?
| | Visual Pathways | 3 | 2023 | 61 | 0.160 |
Why?
| | Interferon-gamma | 1 | 2023 | 791 | 0.160 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2024 | 772 | 0.150 |
Why?
| | Antibodies, Blocking | 1 | 2019 | 38 | 0.150 |
Why?
| | Myelin Proteins | 2 | 2017 | 45 | 0.150 |
Why?
| | Amygdala | 1 | 2021 | 192 | 0.150 |
Why?
| | Viral Vaccines | 1 | 2020 | 107 | 0.150 |
Why?
| | Cell Separation | 2 | 2015 | 311 | 0.150 |
Why?
| | Steroids | 1 | 2020 | 165 | 0.150 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 15 | 0.150 |
Why?
| | Prevalence | 2 | 2024 | 2831 | 0.150 |
Why?
| | Models, Molecular | 3 | 2025 | 1624 | 0.150 |
Why?
| | United States | 3 | 2025 | 15584 | 0.150 |
Why?
| | Child | 13 | 2024 | 22771 | 0.150 |
Why?
| | Intersectoral Collaboration | 1 | 2019 | 60 | 0.150 |
Why?
| | Treatment Outcome | 11 | 2024 | 11389 | 0.150 |
Why?
| | Glutathione S-Transferase pi | 1 | 2018 | 10 | 0.150 |
Why?
| | S100 Calcium Binding Protein beta Subunit | 1 | 2018 | 7 | 0.150 |
Why?
| | Oxidoreductases | 1 | 2019 | 95 | 0.140 |
Why?
| | Cell Lineage | 1 | 2020 | 370 | 0.140 |
Why?
| | Killer Cells, Natural | 3 | 2024 | 475 | 0.140 |
Why?
| | Neurogenesis | 3 | 2016 | 154 | 0.140 |
Why?
| | Communicable Diseases | 1 | 2020 | 165 | 0.140 |
Why?
| | Myelin Proteolipid Protein | 1 | 2018 | 60 | 0.140 |
Why?
| | Peptides | 2 | 2019 | 981 | 0.140 |
Why?
| | Immunoglobulin Variable Region | 3 | 2008 | 81 | 0.140 |
Why?
| | Point Mutation | 1 | 2019 | 243 | 0.140 |
Why?
| | SOXB1 Transcription Factors | 1 | 2018 | 66 | 0.140 |
Why?
| | Cognitive Dysfunction | 1 | 2023 | 441 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 280 | 0.130 |
Why?
| | Skull Neoplasms | 1 | 2017 | 21 | 0.130 |
Why?
| | Spatial Analysis | 1 | 2017 | 23 | 0.130 |
Why?
| | Sphenoid Bone | 1 | 2017 | 15 | 0.130 |
Why?
| | Least-Squares Analysis | 1 | 2017 | 78 | 0.130 |
Why?
| | Mice, Knockout | 9 | 2017 | 3112 | 0.130 |
Why?
| | Cohort Studies | 5 | 2022 | 5897 | 0.130 |
Why?
| | Antibodies, Viral | 4 | 2023 | 668 | 0.130 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2020 | 551 | 0.130 |
Why?
| | Orbital Diseases | 1 | 2017 | 32 | 0.130 |
Why?
| | Albumins | 1 | 2017 | 114 | 0.130 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2017 | 108 | 0.120 |
Why?
| | Protein Structure, Secondary | 2 | 2015 | 368 | 0.120 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2023 | 928 | 0.120 |
Why?
| | Oculomotor Muscles | 1 | 2017 | 85 | 0.120 |
Why?
| | Fibrinogen | 1 | 2017 | 179 | 0.120 |
Why?
| | Microvessels | 1 | 2017 | 93 | 0.120 |
Why?
| | Follow-Up Studies | 3 | 2016 | 5319 | 0.120 |
Why?
| | Interleukin-6 | 1 | 2020 | 781 | 0.120 |
Why?
| | Microscopy, Confocal | 1 | 2017 | 326 | 0.120 |
Why?
| | HEK293 Cells | 4 | 2022 | 747 | 0.120 |
Why?
| | Interferon-beta | 2 | 2025 | 94 | 0.120 |
Why?
| | Adrenal Cortex Hormones | 2 | 2021 | 505 | 0.120 |
Why?
| | Ethics, Research | 1 | 2015 | 30 | 0.120 |
Why?
| | Herpes Zoster Ophthalmicus | 1 | 2015 | 6 | 0.120 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2022 | 680 | 0.120 |
Why?
| | Treatment Failure | 1 | 2016 | 357 | 0.120 |
Why?
| | Microscopy, Fluorescence | 1 | 2017 | 420 | 0.110 |
Why?
| | Eye Infections, Viral | 1 | 2015 | 11 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 378 | 0.110 |
Why?
| | Retinal Neurons | 1 | 2015 | 3 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 373 | 0.110 |
Why?
| | Encephalitis, Varicella Zoster | 1 | 2015 | 17 | 0.110 |
Why?
| | Molecular Dynamics Simulation | 1 | 2017 | 258 | 0.110 |
Why?
| | Aged, 80 and over | 8 | 2021 | 8077 | 0.110 |
Why?
| | Scanning Laser Polarimetry | 1 | 2014 | 2 | 0.110 |
Why?
| | Diffusion Tensor Imaging | 1 | 2015 | 75 | 0.110 |
Why?
| | Protein Structure, Tertiary | 2 | 2015 | 863 | 0.110 |
Why?
| | Plasma Exchange | 1 | 2014 | 18 | 0.110 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2011 | 3836 | 0.110 |
Why?
| | Nerve Fibers | 1 | 2015 | 102 | 0.110 |
Why?
| | Small Molecule Libraries | 2 | 2013 | 107 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 994 | 0.110 |
Why?
| | Rats, Inbred F344 | 2 | 2012 | 265 | 0.100 |
Why?
| | Alanine | 1 | 2015 | 171 | 0.100 |
Why?
| | Nuclear Proteins | 1 | 2019 | 759 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 2057 | 0.100 |
Why?
| | Glycine | 1 | 2015 | 187 | 0.100 |
Why?
| | Erythropoietin | 1 | 2014 | 99 | 0.100 |
Why?
| | Placenta Diseases | 1 | 2013 | 19 | 0.100 |
Why?
| | Peptoids | 1 | 2013 | 1 | 0.100 |
Why?
| | Fetal Death | 1 | 2013 | 59 | 0.100 |
Why?
| | Rats, Sprague-Dawley | 2 | 2016 | 2531 | 0.100 |
Why?
| | Retinal Necrosis Syndrome, Acute | 1 | 2013 | 7 | 0.100 |
Why?
| | Antibody Specificity | 2 | 2011 | 185 | 0.100 |
Why?
| | Neurons | 5 | 2024 | 1636 | 0.100 |
Why?
| | Autism Spectrum Disorder | 2 | 2016 | 427 | 0.100 |
Why?
| | Biomedical Research | 1 | 2019 | 699 | 0.100 |
Why?
| | Syndrome | 2 | 2019 | 380 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2024 | 2195 | 0.090 |
Why?
| | Cell Membrane Permeability | 1 | 2012 | 82 | 0.090 |
Why?
| | Proteome | 2 | 2015 | 495 | 0.090 |
Why?
| | Phenotype | 3 | 2020 | 3209 | 0.090 |
Why?
| | Computer Simulation | 1 | 2017 | 1028 | 0.090 |
Why?
| | Multiprotein Complexes | 2 | 2012 | 171 | 0.090 |
Why?
| | Exanthema | 1 | 2013 | 82 | 0.090 |
Why?
| | Potassium Channels, Inwardly Rectifying | 1 | 2012 | 44 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 1 | 2015 | 678 | 0.090 |
Why?
| | Antigens, CD20 | 2 | 2023 | 35 | 0.090 |
Why?
| | Area Postrema | 1 | 2011 | 2 | 0.090 |
Why?
| | Glutamate Plasma Membrane Transport Proteins | 1 | 2011 | 6 | 0.090 |
Why?
| | Disability Evaluation | 2 | 2026 | 305 | 0.090 |
Why?
| | Cranial Sinuses | 1 | 2011 | 16 | 0.090 |
Why?
| | Excitatory Amino Acid Transporter 2 | 1 | 2011 | 15 | 0.090 |
Why?
| | Drug Discovery | 1 | 2013 | 150 | 0.090 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2011 | 32 | 0.090 |
Why?
| | HLA-DRB1 Chains | 1 | 2012 | 111 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1667 | 0.090 |
Why?
| | Fundus Oculi | 1 | 2011 | 87 | 0.090 |
Why?
| | Mass Spectrometry | 1 | 2015 | 741 | 0.090 |
Why?
| | Cerebral Angiography | 2 | 2011 | 117 | 0.090 |
Why?
| | Endothelial Cells | 1 | 2017 | 847 | 0.090 |
Why?
| | Tissue Culture Techniques | 3 | 2017 | 82 | 0.080 |
Why?
| | Quality of Life | 1 | 2023 | 3082 | 0.080 |
Why?
| | Brain Mapping | 2 | 2024 | 536 | 0.080 |
Why?
| | Fluorescein Angiography | 1 | 2011 | 184 | 0.080 |
Why?
| | Integrin alpha4beta1 | 2 | 2010 | 8 | 0.080 |
Why?
| | Vascular Diseases | 1 | 2013 | 246 | 0.080 |
Why?
| | Cell Line | 3 | 2011 | 2899 | 0.080 |
Why?
| | Neurosurgical Procedures | 1 | 2011 | 205 | 0.080 |
Why?
| | Spinal Puncture | 1 | 2009 | 18 | 0.080 |
Why?
| | Risk Factors | 4 | 2016 | 10661 | 0.080 |
Why?
| | Prognosis | 1 | 2018 | 4162 | 0.080 |
Why?
| | Pregnancy | 5 | 2023 | 7164 | 0.080 |
Why?
| | Research Design | 1 | 2015 | 1124 | 0.070 |
Why?
| | Genes | 1 | 2009 | 229 | 0.070 |
Why?
| | Algorithms | 1 | 2017 | 1818 | 0.070 |
Why?
| | Databases, Factual | 1 | 2015 | 1465 | 0.070 |
Why?
| | Brain Injuries | 1 | 2014 | 506 | 0.070 |
Why?
| | Time Factors | 4 | 2015 | 7039 | 0.070 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 626 | 0.070 |
Why?
| | Blindness | 1 | 2008 | 51 | 0.070 |
Why?
| | Clone Cells | 3 | 2017 | 270 | 0.070 |
Why?
| | Optic Disk | 1 | 2008 | 54 | 0.070 |
Why?
| | Antibody-Producing Cells | 1 | 2007 | 30 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2024 | 3633 | 0.070 |
Why?
| | Transfection | 3 | 2018 | 950 | 0.070 |
Why?
| | Lipid Metabolism | 1 | 2011 | 524 | 0.070 |
Why?
| | Retinal Artery | 1 | 2007 | 17 | 0.070 |
Why?
| | Pregnancy Complications | 1 | 2013 | 591 | 0.070 |
Why?
| | Vision, Low | 1 | 2007 | 17 | 0.070 |
Why?
| | Age of Onset | 2 | 2020 | 549 | 0.070 |
Why?
| | Monitoring, Physiologic | 1 | 2009 | 289 | 0.070 |
Why?
| | Molecular Biology | 2 | 2009 | 60 | 0.070 |
Why?
| | Health | 1 | 2007 | 83 | 0.070 |
Why?
| | von Hippel-Lindau Disease | 1 | 2007 | 12 | 0.060 |
Why?
| | Subacute Sclerosing Panencephalitis | 1 | 2006 | 6 | 0.060 |
Why?
| | Measles virus | 1 | 2006 | 20 | 0.060 |
Why?
| | Visual Fields | 1 | 2007 | 118 | 0.060 |
Why?
| | Nucleocapsid Proteins | 1 | 2006 | 27 | 0.060 |
Why?
| | Bevacizumab | 1 | 2007 | 137 | 0.060 |
Why?
| | Puerperal Disorders | 1 | 2007 | 35 | 0.060 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2007 | 114 | 0.060 |
Why?
| | Vitreous Body | 1 | 2007 | 124 | 0.060 |
Why?
| | Binding, Competitive | 2 | 2019 | 194 | 0.060 |
Why?
| | Cytotoxicity Tests, Immunologic | 2 | 2019 | 37 | 0.060 |
Why?
| | Models, Immunological | 1 | 2006 | 101 | 0.060 |
Why?
| | Angiogenesis Inhibitors | 1 | 2007 | 234 | 0.060 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 5760 | 0.060 |
Why?
| | Injections, Spinal | 2 | 2016 | 109 | 0.060 |
Why?
| | Immunologic Memory | 1 | 2007 | 365 | 0.060 |
Why?
| | Spatio-Temporal Analysis | 2 | 2016 | 38 | 0.060 |
Why?
| | Myelography | 1 | 2025 | 37 | 0.060 |
Why?
| | Membrane Proteins | 1 | 2011 | 1177 | 0.060 |
Why?
| | Fetus | 1 | 2009 | 807 | 0.060 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2025 | 56 | 0.060 |
Why?
| | DNA | 1 | 2011 | 1457 | 0.050 |
Why?
| | Syndecans | 1 | 2004 | 5 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2007 | 550 | 0.050 |
Why?
| | Complementarity Determining Regions | 1 | 2004 | 52 | 0.050 |
Why?
| | Cell Line, Tumor | 4 | 2015 | 3615 | 0.050 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2006 | 281 | 0.050 |
Why?
| | Motor Neuron Disease | 1 | 2004 | 21 | 0.050 |
Why?
| | Risk | 1 | 2007 | 906 | 0.050 |
Why?
| | Child, Preschool | 4 | 2021 | 11772 | 0.050 |
Why?
| | Touch | 1 | 2024 | 38 | 0.050 |
Why?
| | Fistula | 1 | 2024 | 48 | 0.050 |
Why?
| | Cranial Nerve Diseases | 1 | 2004 | 43 | 0.050 |
Why?
| | Granzymes | 1 | 2024 | 50 | 0.050 |
Why?
| | Cryoelectron Microscopy | 1 | 2025 | 208 | 0.050 |
Why?
| | Somatosensory Cortex | 1 | 2024 | 41 | 0.050 |
Why?
| | Ataxia | 1 | 2024 | 70 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 2 | 2025 | 2779 | 0.050 |
Why?
| | Patient Selection | 1 | 2008 | 692 | 0.050 |
Why?
| | Cerebrospinal Fluid Leak | 1 | 2024 | 65 | 0.050 |
Why?
| | Geniculate Bodies | 1 | 2023 | 22 | 0.050 |
Why?
| | Receptors, IgG | 1 | 2023 | 73 | 0.050 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2024 | 222 | 0.050 |
Why?
| | Optic Nerve Neoplasms | 1 | 2023 | 11 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2423 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2022 | 3011 | 0.050 |
Why?
| | Headache | 1 | 2024 | 158 | 0.050 |
Why?
| | Eye Abnormalities | 1 | 2002 | 17 | 0.050 |
Why?
| | Biopsy | 2 | 2017 | 1083 | 0.050 |
Why?
| | Embryonic and Fetal Development | 1 | 2002 | 94 | 0.050 |
Why?
| | Developmental Biology | 1 | 2002 | 23 | 0.050 |
Why?
| | Genetic Techniques | 1 | 2002 | 67 | 0.050 |
Why?
| | Extracellular Matrix Proteins | 1 | 2023 | 157 | 0.050 |
Why?
| | Receptors, Cholinergic | 1 | 2022 | 40 | 0.050 |
Why?
| | Feasibility Studies | 1 | 2006 | 1051 | 0.050 |
Why?
| | Antigens, Surface | 1 | 2022 | 156 | 0.050 |
Why?
| | Meningeal Neoplasms | 1 | 2023 | 97 | 0.050 |
Why?
| | Primates | 1 | 2022 | 133 | 0.040 |
Why?
| | Gene Regulatory Networks | 2 | 2015 | 319 | 0.040 |
Why?
| | Eye | 1 | 2002 | 114 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 2 | 2013 | 383 | 0.040 |
Why?
| | Binding Sites | 2 | 2017 | 1329 | 0.040 |
Why?
| | Glycoproteins | 1 | 2023 | 356 | 0.040 |
Why?
| | Delphi Technique | 1 | 2023 | 326 | 0.040 |
Why?
| | Evoked Potentials, Visual | 1 | 2021 | 41 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2022 | 310 | 0.040 |
Why?
| | Encephalitis Viruses, Tick-Borne | 1 | 2020 | 8 | 0.040 |
Why?
| | Age Factors | 2 | 2021 | 3330 | 0.040 |
Why?
| | Base Sequence | 1 | 2004 | 2200 | 0.040 |
Why?
| | COS Cells | 2 | 2011 | 179 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2025 | 1985 | 0.040 |
Why?
| | Random Allocation | 1 | 2021 | 370 | 0.040 |
Why?
| | Biological Evolution | 1 | 2024 | 493 | 0.040 |
Why?
| | Immunity, Humoral | 1 | 2020 | 117 | 0.040 |
Why?
| | Aging | 2 | 2024 | 1955 | 0.040 |
Why?
| | Dopamine | 1 | 2022 | 306 | 0.040 |
Why?
| | Immunomodulation | 1 | 2020 | 102 | 0.040 |
Why?
| | Stiff-Person Syndrome | 1 | 2019 | 14 | 0.040 |
Why?
| | Serum | 1 | 2019 | 58 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2023 | 752 | 0.040 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2015 | 894 | 0.040 |
Why?
| | Rituximab | 1 | 2020 | 206 | 0.040 |
Why?
| | Models, Biological | 1 | 2007 | 1831 | 0.040 |
Why?
| | Glutamate Decarboxylase | 1 | 2019 | 166 | 0.040 |
Why?
| | Eye Pain | 1 | 2018 | 6 | 0.040 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2018 | 47 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2021 | 922 | 0.040 |
Why?
| | Transcription, Genetic | 2 | 2016 | 1511 | 0.030 |
Why?
| | Survival Analysis | 1 | 2021 | 1332 | 0.030 |
Why?
| | Sequence Alignment | 2 | 2009 | 367 | 0.030 |
Why?
| | Antirheumatic Agents | 1 | 2020 | 309 | 0.030 |
Why?
| | Protein Conformation, alpha-Helical | 1 | 2017 | 19 | 0.030 |
Why?
| | Clonal Deletion | 1 | 2017 | 16 | 0.030 |
Why?
| | Self Tolerance | 1 | 2017 | 26 | 0.030 |
Why?
| | Immunoglobulin Class Switching | 1 | 2017 | 21 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2025 | 3381 | 0.030 |
Why?
| | Recovery of Function | 1 | 2021 | 704 | 0.030 |
Why?
| | Hydrogen Bonding | 1 | 2017 | 169 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2011 | 1314 | 0.030 |
Why?
| | Craniotomy | 1 | 2017 | 82 | 0.030 |
Why?
| | Amino Acid Motifs | 1 | 2017 | 226 | 0.030 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2017 | 151 | 0.030 |
Why?
| | Phosphatidylcholines | 1 | 2017 | 131 | 0.030 |
Why?
| | Lipid Bilayers | 1 | 2017 | 103 | 0.030 |
Why?
| | Animals, Outbred Strains | 1 | 2015 | 6 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2017 | 205 | 0.030 |
Why?
| | Neocortex | 1 | 2016 | 44 | 0.030 |
Why?
| | Chronic Disease | 1 | 2022 | 1834 | 0.030 |
Why?
| | Conserved Sequence | 1 | 2016 | 243 | 0.030 |
Why?
| | Th17 Cells | 1 | 2016 | 109 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 856 | 0.030 |
Why?
| | Influenza Vaccines | 1 | 2020 | 553 | 0.030 |
Why?
| | Microcephaly | 1 | 2016 | 103 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 520 | 0.030 |
Why?
| | Cell Death | 1 | 2017 | 394 | 0.030 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2017 | 367 | 0.030 |
Why?
| | Leukocytes | 1 | 2016 | 299 | 0.030 |
Why?
| | Species Specificity | 1 | 2016 | 577 | 0.030 |
Why?
| | Thermodynamics | 1 | 2017 | 424 | 0.030 |
Why?
| | Cerebral Arterial Diseases | 1 | 2015 | 49 | 0.030 |
Why?
| | Cell Adhesion | 1 | 2016 | 456 | 0.030 |
Why?
| | Spinal Cord Diseases | 1 | 2014 | 44 | 0.030 |
Why?
| | Spleen | 1 | 2016 | 517 | 0.030 |
Why?
| | Intellectual Disability | 1 | 2016 | 178 | 0.030 |
Why?
| | Immune Tolerance | 1 | 2016 | 384 | 0.030 |
Why?
| | Calcium Signaling | 1 | 2016 | 248 | 0.030 |
Why?
| | CD59 Antigens | 1 | 2014 | 20 | 0.030 |
Why?
| | Nogo Proteins | 1 | 2013 | 10 | 0.030 |
Why?
| | SOXC Transcription Factors | 1 | 2013 | 5 | 0.030 |
Why?
| | Cell Adhesion Molecules, Neuronal | 1 | 2014 | 41 | 0.030 |
Why?
| | Sodium Channels | 1 | 2014 | 62 | 0.030 |
Why?
| | Oligodendrocyte Transcription Factor 2 | 1 | 2013 | 23 | 0.030 |
Why?
| | Narcolepsy | 1 | 2013 | 25 | 0.020 |
Why?
| | Multigene Family | 1 | 2013 | 205 | 0.020 |
Why?
| | Immunoglobulin Idiotypes | 1 | 2012 | 28 | 0.020 |
Why?
| | Pyrans | 1 | 2012 | 5 | 0.020 |
Why?
| | Neurodevelopmental Disorders | 1 | 2016 | 224 | 0.020 |
Why?
| | Parkinson Disease | 1 | 2019 | 580 | 0.020 |
Why?
| | Interneurons | 1 | 2013 | 124 | 0.020 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2015 | 272 | 0.020 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2017 | 727 | 0.020 |
Why?
| | Autoimmune Diseases | 1 | 2016 | 469 | 0.020 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2013 | 198 | 0.020 |
Why?
| | Surface Plasmon Resonance | 1 | 2012 | 89 | 0.020 |
Why?
| | Molecular Docking Simulation | 1 | 2012 | 117 | 0.020 |
Why?
| | Binding Sites, Antibody | 1 | 2012 | 42 | 0.020 |
Why?
| | Phlebography | 1 | 2011 | 40 | 0.020 |
Why?
| | O Antigens | 1 | 2011 | 8 | 0.020 |
Why?
| | Vaccination | 1 | 2020 | 1483 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2011 | 206 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2011 | 203 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2938 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2011 | 309 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2012 | 577 | 0.020 |
Why?
| | Protein Array Analysis | 1 | 2011 | 58 | 0.020 |
Why?
| | Genome | 1 | 2013 | 309 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2011 | 330 | 0.020 |
Why?
| | Ligands | 1 | 2013 | 670 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2011 | 135 | 0.020 |
Why?
| | High-Throughput Screening Assays | 1 | 2012 | 162 | 0.020 |
Why?
| | Embryo, Mammalian | 1 | 2011 | 237 | 0.020 |
Why?
| | Tubulin | 1 | 2011 | 146 | 0.020 |
Why?
| | Calcium-Binding Proteins | 1 | 2011 | 218 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2015 | 1044 | 0.020 |
Why?
| | Pilot Projects | 1 | 2016 | 1839 | 0.020 |
Why?
| | Biological Assay | 1 | 2010 | 128 | 0.020 |
Why?
| | Palmitic Acid | 1 | 2009 | 42 | 0.020 |
Why?
| | Quantum Dots | 1 | 2009 | 38 | 0.020 |
Why?
| | Diagnostic Techniques, Neurological | 1 | 2009 | 11 | 0.020 |
Why?
| | Hospitalization | 1 | 2019 | 2314 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1736 | 0.020 |
Why?
| | Antiviral Agents | 1 | 2015 | 763 | 0.020 |
Why?
| | Water | 1 | 2012 | 471 | 0.020 |
Why?
| | Immunoglobulins | 1 | 2009 | 162 | 0.020 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2009 | 156 | 0.020 |
Why?
| | Pyrazoles | 1 | 2012 | 499 | 0.020 |
Why?
| | Protein Kinase C | 1 | 2009 | 253 | 0.020 |
Why?
| | Genetic Markers | 1 | 2009 | 345 | 0.020 |
Why?
| | Virion | 1 | 2009 | 114 | 0.020 |
Why?
| | Interferon beta-1b | 1 | 2008 | 2 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2009 | 790 | 0.020 |
Why?
| | Interferon beta-1a | 1 | 2008 | 14 | 0.020 |
Why?
| | Databases, Genetic | 1 | 2009 | 248 | 0.020 |
Why?
| | DNA, Viral | 1 | 2009 | 366 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2009 | 477 | 0.020 |
Why?
| | Alzheimer Disease | 1 | 2013 | 607 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2009 | 1272 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2012 | 1130 | 0.010 |
Why?
| | Glioma | 1 | 2010 | 428 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2008 | 774 | 0.010 |
Why?
| | Cytokines | 1 | 2013 | 2099 | 0.010 |
Why?
| | Trochlear Nerve Diseases | 1 | 2004 | 9 | 0.010 |
Why?
| | Oculomotor Nerve Diseases | 1 | 2004 | 14 | 0.010 |
Why?
| | Abducens Nerve Diseases | 1 | 2004 | 12 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2010 | 1489 | 0.010 |
Why?
| | Evidence-Based Medicine | 1 | 2008 | 724 | 0.010 |
Why?
| | Calcium | 1 | 2009 | 1183 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2006 | 823 | 0.010 |
Why?
| | Infant | 1 | 2017 | 10014 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2621 | 0.010 |
Why?
| | Computational Biology | 1 | 2006 | 677 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1674 | 0.010 |
Why?
| | Practice Guidelines as Topic | 1 | 2008 | 1560 | 0.010 |
Why?
| | Signal Transduction | 1 | 2009 | 5220 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2004 | 6033 | 0.010 |
Why?
|
|
Bennett's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|